Loteprednol combined with sodium hyaluronate in the treatment of dry eye disease and its effect on TNF-&#945; and CXCL10 in tears.

Chen, W; Shi, X L; He, X H; Mao, Y H; Li, C; Dong, N

Loteprednol combined with sodium hyaluronate in the treatment of dry eye disease and its effect on TNF-α and CXCL10 in tears.

Chen, W; Shi, X L; He, X H; Mao, Y H; Li, C; Dong, N.

Afiliação

Chen W; Eye Institute & Affiliated Xiamen Eye Center, Xiamen University Medical College, Xiamen, Fujian, China.
Shi XL; Eye Institute & Affiliated Xiamen Eye Center, Xiamen University Medical College, Xiamen, Fujian, China.
He XH; Eye Institute & Affiliated Xiamen Eye Center, Xiamen University Medical College, Xiamen, Fujian, China.
Mao YH; Eye Institute & Affiliated Xiamen Eye Center, Xiamen University Medical College, Xiamen, Fujian, China.
Li C; Eye Institute & Affiliated Xiamen Eye Center, Xiamen University Medical College, Xiamen, Fujian, China.
Dong N; Eye Institute & Affiliated Xiamen Eye Center, Xiamen University Medical College, Xiamen, Fujian, China.

J Biol Regul Homeost Agents ; 34(5): 1825-1829, 2020.

Article em En | MEDLINE | ID: mdl-33103412

Assuntos

Síndromes do Olho Seco; Ácido Hialurônico/uso terapêutico; Etabonato de Loteprednol/uso terapêutico; Quimiocina CXCL10; Síndromes do Olho Seco/tratamento farmacológico; Humanos; Soluções Oftálmicas; Lágrimas; Fator de Necrose Tumoral alfa

Palavras-chave

CXCL10; TNF-α; dry eye; loteprednol; sodium hyaluronate

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes do Olho Seco / Etabonato de Loteprednol / Ácido Hialurônico Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google